Terms: = Leukemia AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI
7662 results:
1. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
Zhou T; Chen ML; Zhang CY; Liu XY; Wang ZZ; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):225-232. PubMed ID: 38716593
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H; Wen X; Zheng H
Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
[TBL] [Abstract] [Full Text] [Related]
3. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract] [Full Text] [Related]
4. Fmoc-FF hydrogels and nanogels for improved and selective delivery of dexamethasone in leukemic cells and diagnostic applications.
Gallo E; Diaferia C; Smaldone G; Rosa E; Pecoraro G; Morelli G; Accardo A
Sci Rep; 2024 Apr; 14(1):9940. PubMed ID: 38688930
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France.
Alcazer V; Le Meur G; Roccon M; Barriere S; Le Calvez B; Badaoui B; Spaeth A; Kosmider O; Freynet N; Eveillard M; Croizier C; Chevalier S; Sujobert P
Lancet Digit Health; 2024 May; 6(5):e323-e333. PubMed ID: 38670741
[TBL] [Abstract] [Full Text] [Related]
6. True Donor Cell leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations-Brief Report.
Hoffmann M; Banz Y; Halter J; Schoumans J; Tchinda J; Bacher U; Pabst T
Curr Oncol; 2024 Apr; 31(4):2067-2075. PubMed ID: 38668056
[TBL] [Abstract] [Full Text] [Related]
7. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical Analysis of Mitoxantrone Liposome in the Treatment of Children with High-Risk Acute Myeloid leukemia].
Jiao YQ; Xiong H; Chen Z; Yang L; Tao F; Sun M; Qi SS; Lu WJ; Wang Z; DU Y; Luo LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):365-369. PubMed ID: 38660837
[TBL] [Abstract] [Full Text] [Related]
9. Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer.
Jia L; Yang H; Liu Y; Zhou Y; Li G; Zhou Q; Xu Y; Huang Z; Ye F; Ye J; Liu A; Ji C
J Nanobiotechnology; 2024 Apr; 22(1):198. PubMed ID: 38649957
[TBL] [Abstract] [Full Text] [Related]
10. Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells.
Alsulays BB; Aodah AH; Ahmed MM; Anwer MK
Int J Nanomedicine; 2024; 19():3461-3473. PubMed ID: 38617799
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases].
Li XP; Li Y; Liu L; Yuan ZT; Wang YC; Dong YC; Zhang DS; Feng J; Chen YN; Wang SB
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):128-133. PubMed ID: 38604788
[No Abstract] [Full Text] [Related]
12. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract] [Full Text] [Related]
13. Methodological challenges in the development of endpoints for myelofibrosis clinical trials.
Barosi G; Tefferi A; Gangat N; Szuber N; Rambaldi A; Odenike O; Kröger N; Gagelmann N; Talpaz M; Kantarjian H; Gale RP
Lancet Haematol; 2024 May; 11(5):e383-e389. PubMed ID: 38604205
[TBL] [Abstract] [Full Text] [Related]
14. Patterns of follow-up care in adult blood cancer survivors-Prospective evaluation of health-related outcomes, resource use, and quality of life.
Lax H; Baum J; Lehmann N; Merkel-Jens A; Beelen DW; Jöckel KH; Dührsen U
Cancer Med; 2024 Apr; 13(7):e7095. PubMed ID: 38549460
[TBL] [Abstract] [Full Text] [Related]
15. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
16. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
[No Abstract] [Full Text] [Related]
17. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
[No Abstract] [Full Text] [Related]
18. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
[TBL] [Abstract] [Full Text] [Related]
19. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Chien KS; Ong F; Kim K; Li Z; Kanagal-Shamanna R; DiNardo CD; Takahashi K; Montalban-Bravo G; Hammond D; Sasaki K; Pierce SA; Kantarjian HM; Garcia-Manero G
Cancer Med; 2024 Mar; 13(5):e7093. PubMed ID: 38497538
[TBL] [Abstract] [Full Text] [Related]
20. Survival of European adolescents and young adults diagnosed with cancer in 2010-2014.
Trama A; Botta L; Stiller C; Visser O; Cañete-Nieto A; Spycher B; Bielska-Lasota M; Katalinic A; Vener C; Innos K; Marcos-Gragera R; Paapsi K; Guevara M; Demuru E; Mousavi SM; Blum M; Eberle A; Ferrari A; Bernasconi A; Lasalvia P;
Eur J Cancer; 2024 May; 202():113558. PubMed ID: 38489859
[TBL] [Abstract] [Full Text] [Related]
[Next]
